Press Releases

Mar 11, 2021 AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

Mar 10, 2021 AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 08, 2021 AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

Mar 04, 2021 AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

Feb 24, 2021 AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

Feb 16, 2021 AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

Feb 10, 2021 AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

Feb 05, 2021 AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials

Jan 29, 2021 AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

Jan 15, 2021 AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

1 2 3 4 5 6 7 8 9

<< < > >>